LONDON – It’s no secret that American citizens pay the most for drugs, but the extent of the disparity is laid bare in a new index of the prices of 13 medicines in 50 countries worldwide.

Analysis and data insight

Gene therapy companies recover after their stock market slide

November 22, 2019

By Peter Winter

No Comments

After a two-month 32% swoon in the value of the BioWorld Gene Therapy index, it has managed to recover 6% of that loss since the end of September. Contributing to the recovery was Menlo Park, Calif.-based Adverum Biotechnologies Inc., whose shares (NASDAQ:ADVM) jumped almost 80% in the period.

Money raised by biopharma: 2019 vs. 2018

November 22, 2019

No Comments

Total raised in public, private and other financings of biopharma companies, comparing 2019 vs. 2018.

Analysis and data insight

Biopharma companies securing their position in cell and gene therapy

November 22, 2019

By Peter Winter

No Comments

It has been a productive year for cell and gene therapy companies, and every week the sector never fails to generate exciting news flow to keep investors engaged. Given these ongoing developments, it is not surprising that companies involved in the area continue to attract financing and strategic partners.

Biopharma money raised: Jan. 1-Nov. 21, 2019

November 22, 2019

No Comments

Year-to-date money raised in public, private and other financings of biopharma companies.

Bioworld MedTech’s Oncology Extra
BioWorld MedTech
Keeping you up to date on recent developments in oncology.
FDA gives thumbs up to Cochlear’s implantable bone conduction hearing system
BioWorld MedTech
The U.S. FDA has cleared Cochlear Ltd.’s newest cochlear implant, the Osia 2 system, an active implantable bone conduction hearing system. Unlike Cochlear’s...
Analysis by U.K. startup Medbelle highlights extent of drug pricing disparity
BioWorld
LONDON – It’s no secret that American citizens pay the most for drugs, but the extent of the disparity is laid bare in a new index of the prices of 13 medicines...
Buoyed by optimism and love of family, former FDA chief Frank Young leaned into storms
BioWorld
Commissioner of the FDA for five years starting in 1984, Frank Young relished his position “at the vortex of controversy” as he sought to deal with the AIDS...
Biopharma companies continue their strong momentum in November
BioWorld
After being in the doldrums for the majority of the year, public biopharmaceutical companies, it appears, have turned the corner and are now on a major upswing.

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Analysis and data insight RSS

Popular Stories

BioWorld Premium

Analysis and data insight
RSS